데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
55224-05-0CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@H]2OC(=O)O[C@@]21CNKLGIWNNVDPGCA-ZDYKNUMJSA-N55224-05-0DTXSID801031707CHEMBL4788726CHEBI:135881안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Davercin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains. It has broad-spectrum activity against various Gram-positive and Gram-negative bacteria (MICs = 0.02-50 μg/ml). Davercin is non-toxic to mice and rats (LD50s = 4.05 and 5.9 g/kg, respectively). Formulations containing davercin have been used to treat a variety of urogenital bacterial infections.
용도Davercin (erythromycin A cyclic 11,12-carbonate) is a first generation semi-synthetic erythromycin. Davercin is prepared by coupling the 11- and 12-OH groups to form a cyclic carbonate. This simple modification improves the stability and hydrophobicity of the macrocyclic structure. Davercin shows comparable or better in vitro potency, low host toxicity and improved pharmacokinetics compared with erythromycin.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…